Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 6/20 | 0.39 |
| ▸ | WHR1 | P49842 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 2/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | DNM2 | P50570 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6679553 | 0.88 | FLT3 (0.41) | FLT3BLMKCNH2 | |
| SCHEMBL6676122 | 0.87 | FLT3 (0.34) | FLT3BLM | |
| SCHEMBL2774178 | 0.84 | KCNH2 (0.40) | NCF1KDM1ARCOR1EHMT2SLC2A1 | |
| SCHEMBL2776366 | 0.82 | SCN9A (0.42) | FLT3NCF1KDM1ARCOR1EHMT2 | |
| SCHEMBL2776640 | 0.81 | KDM1A (0.42) | WHR1KDM1ARCOR1EHMT2BLM | |
| SCHEMBL6677683 | 0.81 | KCNH2 (0.36) | WHR1NCF1KDM1ARCOR1EHMT2 | |
| SCHEMBL6673922 | 0.80 | DNM2 (0.37) | WHR1NCF1KDM1ARCOR1EHMT2 | |
| SCHEMBL6679202 | 0.80 | KCNH2 (0.42) | NCF1KDM1ARCOR1EHMT2KCNH2 | |
| SCHEMBL6678946 | 0.79 | NCF1 (0.44) | NCF1KDM1ARCOR1EHMT2SLC2A1 | |
| SCHEMBL2776163 | 0.79 | POLB (0.41) | DNM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1468688-A2 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | Auckland Uniservices Limited (NZ) | 2004-10-20 | — | — | EP | disclosed |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | NPM1, DUOX1, NOX5 | FLT3 661/4885WHR1 2005/4885NCF1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.